Clinical Trial: A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545681) titled 'A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria' on April 16.

Brief Summary: The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

Study Start Date: April 20

Study Type: INTERVENTIONAL

Condition: Malaria, Falciparum

Intervention: DRUG: GSK3772701 600 mg

A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.

DRUG: GSK3772701 900 mg

A 900 mg dose of GSK3772701 admin...